Our mission is to accelerate the development of stem cell research and treatments. We will therefore sponsor and support clinical trials starting in the first half of 2023.
Realizing the potential
Studies have shown that mesenchymal stromal cells (a type of stem cells) reduce inflammation, modulate the immune system, and regenerate damaged or diseased tissues, promoting better health and quality of life. This makes them an ideal candidate to tackle a number of chronic diseases where there is currently no good other option.
Cellcolabs was founded to solve the problem of poor availability and high prices of high-quality stem cells for research and treatments. We build on the findings and clinical experience from more than 20 years of stem cell research at Karolinska Institutet, including 167 published scientific papers with 30 000 citations (as of 2021), resulting in exceptional stem cell quality. Our cells are mesenchymal stromal cells (MSCs) derived from the bone marrow of healthy young donors, and have previously been approved by the Swedish Medical Products Agency for use in two academic clinical trials. Our next step is to sponsor larger scale international trials.
Current Clinical Trials
As with most other stem cell products, our stem cells are considered an investigational medicinal product, as there is no market approval yet. The underlying mechanism of stem cell treatment still remains unclear and more data and research is needed. This is why an important part of Cellcolabs' work is to drive scale in clinical trials.
Cellcolabs' cells will be used in international clinical trials for various conditions, including Ageing Frailty, Osteoarthrosis (OA), and other cognitive impairments and orthopedic conditions.
Connect with us!
If you would like to learn more and participate in our clinical trials, please fill out the form below or email email@example.com and we will be in touch. We will do our best to answer your questions.
Autologous stem cell treatments use cells derived form the patient's own body. In practice, this often involves extracting MSCs from the fat tissue and injecting the patient with a concentrate including stem cells from the fat. This treatment option is widespread today since it is not classified as a medicinal product. This however also means that there is no control from medical authorities such as EMA and FDA.
Allogeneic stem cell treatments use the cells obtained from a donor. Cellcolabs' cells are harvested from the bone marrow of healthy donors 18-28 years old, and cultivated in our production facility at the Karolinska Institute Campus in Stockholm.There are various advantages with allogeneic MSC treatments produced by companies that follow the EU or US regulations. The quality is strictly regulated and controlled, meaning that we can be certain that the patient receives the intended amount and potency of cells. There is data indicating that MSCs from younger people are more potent than from older ones, which is why Cellcolabs' donors are young and rigorously screened. One donor can provide enough cells to more than 100 patients, and the cells are cryopreserved and readily available "off-the-shelf", enabling a comfortable experience for the patient and fast turnaround times for the healthcare system.